Get informed when a big investor buys or sells
+ Follow-20.86%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Nektar Therapeutics (NKTR) currently reports a ROE of -20.86%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore Nektar Therapeutics's ROE history and peer comparisons.
Nektar Therapeutics's ROE of -20.86% is lower than the Healthcare sector average of 13.1%. That is roughly 259.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Nektar Therapeutics's current -20.86% should be judged against Healthcare norms (sector average: 13.1%) and against NKTR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -20.86%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Nektar Therapeutics, and consider following NKTR for alerts when major investors trade the stock.
Nektar Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -20.86% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NKTR with unrelated industries.